# Luisa Imberti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3389538/publications.pdf

Version: 2024-02-01

| 38 | 5,913 | 304368 | 329751 |
|---|---|---|---|
| papers | citations | 22 h-index | 37 g-index |

| 43 | 43 | 43 | 10530 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, . | 6.0 | 1,983 |
| 2 | Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, . | 6.0 | 1,749 |
| 3 | Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, . | 5.6 | 357 |
| 4 | An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 2021, 6, . | 2.3 | 269 |
| 5 | Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598. | 13.7 | 216 |
| 6 | Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell, 2021, 184, 1836-1857.e22. | 13.5 | 167 |
| 7 | Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nature Medicine, 2022, 28, 1050-1062. | 15.2 | 144 |
| 8 | <scp>I</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871. | 1.5 | 140 |
| 9 | The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119. | 3.3 | 110 |
| 10 | Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clinical Immunology, 2010, 136, 217-227. | 1.4 | 108 |
| 11 | Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. Journal of Allergy and Clinical Immunology, 2007, 120, 892-899. | 1.5 | 95 |
| 12 | The Different Extent of B and T Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapies in SCID Patients with Adenosine Deaminase Deficiency. Journal of Immunology, 2010, 185, 7713-7722. | 0.4 | 62 |
| 13 | Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2013, 11, 188. | 1.8 | 46 |
| 14 | Thymic and Bone Marrow Output in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2011, 31, 540-549. | 2.0 | 35 |
| 15 | Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, . | 5.6 | 35 |
| 16 | Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 726-734. | 1.4 | 34 |
| 17 | Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2019, 25, 1196-1201. | 1.4 | 34 |
| 18 | Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer Journal, 2021, 11, 151. | 2.8 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Exosomes in Tumor Angiogenesis. Methods in Molecular Biology, 2016, 1464, 25-34. | 0.4 | 32 |
| 20 | IFNÎ² bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assaysâ˜†. Journal of Neuroimmunology, 2007, 189, 102-110. | 1.1 | 29 |
| 21 | Assessment of T-Cell receptor Î²-chain diversity by heteroduplex analysis. Human Immunology, 1996, 48, 12-22. | 1.2 | 26 |
| 22 | Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clinical Immunology, 2012, 145, 19-26. | 1.4 | 24 |
| 23 | Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient. PLoS ONE, 2012, 7, e34493. | 1.1 | 21 |
| 24 | Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection. Journal of Neuroimmunology, 2020, 345, 577282. | 1.1 | 20 |
| 25 | Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Multiple Sclerosis Journal, 2012, 18, 788-798. | 1.4 | 19 |
| 26 | Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C. Frontiers in Immunology, 2022, 13, 841126. | 2.2 | 18 |
| 27 | Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients. Journal of Translational Medicine, 2012, 10, 94. | 1.8 | 15 |
| 28 | Detection of newly produced T and B lymphocytes by digital PCR in blood stored dry on nylon flocked swabs. Journal of Translational Medicine, 2017, 15, 70. | 1.8 | 13 |
| 29 | Sex differences in a cohort of COVID-19 Italian patients hospitalized during the first and second pandemic waves. Biology of Sex Differences, 2021, 12, 45. | 1.8 | 13 |
| 30 | Transfer of myxovirus-protein-A mRNA assay for interferon-Î² bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1235-1238. | 1.4 | 11 |
| 31 | Circulating microRNAs and Their Role in Multiple Myeloma. Non-coding RNA, 2019, 5, 37. | 1.3 | 10 |
| 32 | Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655. | 0.6 | 10 |
| 33 | Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis. Drugs and Aging, 2020, 37, 739-746. | 1.3 | 7 |
| 34 | Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy. Journal of Neuroimmunology, 2014, 277, 6-12. | 1.1 | 6 |
| 35 | Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients. , 2022, 1, . | | 5 |
| 36 | Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy. Scientific Reports, 2019, 9, 16605. | 1.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-Î² therapy of multiple sclerosis patients. Journal of Translational Medicine, 2020, 18, 169. | 1.8 | 3 |
| 38 | Long-Lasting Production of New T and B Cells and T-Cell Repertoire Diversity in Patients with Primary Immunodeficiency Who Had Undergone Stem Cell Transplantation: A Single-Centre Experience. Journal of Immunology Research, 2014, 2014, 1-10. | 0.9 | 1 |